Immix Biopharma's positive clinical results for NXC-201 in the NEXICART-1 Phase 1b/2a trial indicate a potential breakthrough in treating DARZALEX-relapsed or refractory AL amyloidosis patients. This news is highly relevant and important for investors, as it demonstrates the company's progress in developing effective treatments. The positive results are likely to drive the stock price higher in the short term, as investors react to the promising data.